Arcosa Shareholders Approve $8.5B CRH Deal. Does the Vote De-Risk a First-Quarter 2027 Closing?
Arcosa, Inc. (ACA) shareholders approved an $8.5B acquisition by CRH plc (CRH) at $150 per share. The vote had 80.8% participation, with 39.6M votes in favor. CRH expects the deal to close in Q1 2027, pending regulatory approvals. CRH values the deal at 11.5x estimated 2026 adjusted EBITDA, with $175M in annual cost synergies expected by year three.
How this was made
The 30-second read
Why it matters
The approval clears a key hurdle, moving the transaction toward a 2027 close pending antitrust clearance.
Market read
Deal approval reduces uncertainty, likely supporting ACA and CRH stock performance.
What to watch
Potential integration challenges and cost‑synergy execution risk.
Background
Arcosa is a leading aggregates and engineered structures provider; CRH is a global building materials group.
Ticker impact
Arcosa shareholders approved the $8.5B cash acquisition by CRH, removing seller‑side approval risk.
ACA may rally on approval; CRH may see modest upside as financing risk eases.
Approval removes a major condition; financing already secured.
CRH secured shareholder approval for its $150‑per‑share, $8.5B acquisition of Arcosa.
CRH may experience a modest price lift as deal risk declines.
Deal now only faces regulatory clearance; financing already in place.
Market effects
Consolidation in aggregates and construction materials sector may pressure peers.
U.S. construction‑materials market sees increased concentration.
Large‑scale M&A adds to overall M&A activity metrics.
Counterpoint
Regulatory antitrust risk remains; delays could depress both stocks.
Key entities
- CompanyArcosa, Inc.
Target of the acquisition.
- CompanyCRH plc
Acquirer.
